Form: 3

Initial statement of beneficial ownership of securities

November 9, 2017

FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Opko Health, Inc.
 2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2017		 3. Issuer Name and Ticker or Trading Symbol
VBI Vaccines Inc/BC [VBIV]
(Last)
(First)
(Middle)
4400 BISCAYNE BLVD.		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MIAMI, FL 33137		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 6,023,014 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Opko Health, Inc.
4400 BISCAYNE BLVD.
MIAMI, FL 33137		     X    

Signatures

Adam Logal, Senior Vice President, CFO 11/09/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) In June 2012, OPKO acquired a 50% stock ownership in SciVac Ltd., a privately held Israeli corporation ("Old SciVac"). In July 2015, Old SciVac completed a reverse takeover (the "Transaction") of Levon Resources Ltd., a Canadian corporation and Levon changed its name to "SciVac Therapeutics Inc." ("SciVac"). At the time the Transaction became effective, OPKO's Old SciVac Shares were exchanged for 185,129,317 common shares of SciVac, and OPKO became the beneficial owner of approximately 24.5% of SciVac. SciVac acquired VBI Vaccines (Delaware) Inc., a Delaware corporation in May 2016, and changed its name to "VBI Vaccines Inc." Subsequently in 2016, OPKO participated in a private placement of VBI shares and also received additional shares of VBI in connection with an anti-dilution clause with respect to the merger in 2016. OPKO's percentage ownership was then approximately 15.1%. At the time of these transactions, the issuer was a foreign private issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.